Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer.

ABSTRACT:

Purpose

Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC.

Methods

We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS).

Results

437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, p = 0.284) in either univariate

SUBMITTER: Domergue C 

PROVIDER: S-EPMC9139240 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature